nicotine transdermal patches
Recently Published Documents


TOTAL DOCUMENTS

9
(FIVE YEARS 1)

H-INDEX

5
(FIVE YEARS 0)

2013 ◽  
Vol 91 (3) ◽  
pp. 520-529 ◽  
Author(s):  
Wiwat Pichayakorn ◽  
Jirapornchai Suksaeree ◽  
Prapaporn Boonme ◽  
Wirach Taweepreda ◽  
Thanaporn Amnuaikit ◽  
...  


2012 ◽  
Vol 411-412 ◽  
pp. 81-90 ◽  
Author(s):  
Wiwat Pichayakorn ◽  
Jirapornchai Suksaeree ◽  
Prapaporn Boonme ◽  
Thanaporn Amnuaikit ◽  
Wirach Taweepreda ◽  
...  




2006 ◽  
Vol 4 (6) ◽  
pp. 583-589 ◽  
Author(s):  
Cho Y. Lam ◽  
Jennifer A. Minnix ◽  
Jason D. Robinson ◽  
Paul M. Cinciripini

The U.S. Department of Health and Human Services' Clinical Practice Guidelines have established both nicotine and nonnicotine-based pharmacotherapies as efficacious treatments for smoking cessation. Smokers attempting to quit smoking can significantly increase their chances by using one of several first-line agents, including nicotine transdermal patches, gum, nasal spray, inhalers, tablets, and the antidepressant bupropion. Those who cannot use either bupropion or nicotine replacement therapy because of contraindications or lack of effectiveness may benefit from the second-line treatment nortriptyline. This article also discusses several novel compounds for smoking cessation.



2003 ◽  
Vol 29 (8) ◽  
pp. 843-853 ◽  
Author(s):  
Thaned Pongjanyakul ◽  
Sompol Prakongpan ◽  
Aroonsri Priprem


2000 ◽  
Vol 183 (3) ◽  
pp. 778
Author(s):  
Steven J. Serra ◽  
Julia A. Robertson ◽  
John C. Carey


2000 ◽  
Vol 26 (6) ◽  
pp. 635-642 ◽  
Author(s):  
Thaned Pongjanyakul ◽  
Sompol Prakongpan ◽  
Aroonsri Priprem


1992 ◽  
Vol &NA; (837) ◽  
pp. 26
Author(s):  
&NA;


Sign in / Sign up

Export Citation Format

Share Document